CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Magstim RapidStim2 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02370875
NCT02370875N/ACompleted
CompareCT.gov

Combined Effects of rTMS and Botulinum Toxin in Benign Essential Blepharospasm: A Novel Approach

University of Florida·interventional·Posted Feb 25, 2015·Updated Sep 15, 2023

In Brief

A clinical study evaluating Magstim RapidStim2 and Sham Magstim RapidStim2 for Benign Essential Blepharospasm. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therapy can be easily combined with BoNT injections to enhance the effects of BoNT in BEB.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Essential Blepharospasm
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 25, 2015
Enrollment StartFeb 1, 2015
Primary CompletionMay 1, 2017
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.4 years ago

Interventions

Magstim RapidStim2device

Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.

Sham Magstim RapidStim2device

Same procedure as real rTMS without stimulating the cerebral cortex.